Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.41 |
| ▸ | ULK1 | O75385 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179470 | 1.00 | NUDT1 (0.41) | NUDT1ULK1KDM4ELRRK2CYP1A2 | |
| SCHEMBL179498 | 1.00 | NUDT1 (0.41) | NUDT1ULK1KDM4ELRRK2CYP1A2 | |
| SCHEMBL251822 | 0.84 | ULK1 (0.43) | NUDT1ULK1KDM4ELRRK2CYP1A2 | |
| SCHEMBL12688252 | 0.83 | ULK1 (0.41) | NUDT1ULK1KDM4ELRRK2CYP1A2 | |
| SCHEMBL18879241 | 0.83 | ULK1 (0.41) | NUDT1ULK1KDM4ELRRK2CYP1A2 | |
| SCHEMBL179474 | 0.83 | BCL6 (0.43) | NUDT1KDM4EL3MBTL1 | |
| SCHEMBL179460 | 0.83 | BCL6 (0.43) | NUDT1KDM4EL3MBTL1 | |
| SCHEMBL179422 | 0.83 | BCL6 (0.43) | NUDT1KDM4EL3MBTL1 | |
| SCHEMBL24092767 | 0.83 | ULK1 (0.42) | NUDT1ULK1KDM4ELRRK2CYP1A2 | |
| SCHEMBL250959 | 0.83 | ULK1 (0.42) | NUDT1ULK1KDM4ELRRK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522146-B2 | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2016-02-04 | — | — | US | disclosed |
| US-9206182-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-8828998-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | NUDT1 791/4885ULK1 213/4885KDM4E 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.